Christie Scheuerell
YOU?
Author Swipe
View article: Parent‐Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients With <i>BRCA 1/2</i>–Mutated Cancer or PARP‐Sensitive Tumor Types
Parent‐Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients With <i>BRCA 1/2</i>–Mutated Cancer or PARP‐Sensitive Tumor Types Open
Veliparib (ABT‐888) is a novel oral poly‐ADP‐ribose polymerase (PARP) inhibitor that is being developed for the treatment of hematologic malignancies and solid tumors. Although the pharmacokinetics of veliparib have been studied in combina…